Fantastic therapy, 5 patients with lupus erythema are saved

Author:Journal of China Science Time:2022.09.19

Wen | Zhao Xixi

CAR-T cells. Image source: Christoph Burgstedt

"Nature-Medicine" published a paper on September 15, which reported that five systemic lupus erythematosus patients were relieved for 17 months after CAR-T cell therapy.

Systemic lupus erythematosus is an autologous immunity rheumatism, with a global population incidence of about 0.1%, high in young women. This lifelong disease is caused by its own antibodies (immune defense molecules attacking its own cells), affecting joints and skin, and may cause severe damage to organs, including kidney, brain, and heart.

Most patients are treated with glucocorticoids and B cell therapy for T cells or antibodies. However, these treatments are often invalid, and there are currently no healing therapy.

Georg Schett at the University of Ellangen, Germany, and colleagues used the transformed anti -CD19 chimeric antigen T cells (CAR) T cells to treat 5 patients with refractory and systemic lupus erythematosus (4 women, 1 Men, the median age is 22 years old). These cells are designed to remove B cells that produce antibodies by targeting CD19 proteins generated on its surface.

Subsequent studies (3 to 17 months after treatment) found that all patients have experienced improvement of symptoms, including the relief of the involvement of internal organs, and the disappearance of their own antibodies related to disease, and no traditional treatment. Common side effects related to CAR-T cell therapy are mild (such as fever), and no infection is observed.

Although these findings may propose a new treatment option for patients with systemic lupus erythematosus, they still need to follow up in more clinical trials to determine the safety and safety and of the car-T cell therapy in this situation. Effective.

Related thesis information:

https://doi.org/10.1038/s41591-022-02017-5

"China Science News" (2022-09-19 The 2nd edition of the original title "New therapy is expected to cure lupus erythematosus")

Edit | Zhao Lu

Capture | Zhihai

- END -

August 3, 2022, the epidemic situation of Xin Crown Pneumonia in Guangdong Province

At 0-24 on August 2, there were no new local diagnosis cases in the province; 1 ca...

Haoyuan Pharmaceutical disclosed the 2022 semi -annual report to achieve revenue of 621 million yuan

On August 25, Hao Yuan Pharmaceutical (Code: 688131.SH) released the 2022 semi -annual performance report.From January 1, 2022-June 30, 2022, the company realized operating income of 621 million yuan,